MX2011009810A - Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. - Google Patents
Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.Info
- Publication number
- MX2011009810A MX2011009810A MX2011009810A MX2011009810A MX2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- binding proteins
- binding
- fgf
- bispecific
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000023732 binding proteins Human genes 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 abstract 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101710146873 Receptor-binding protein Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16402309P | 2009-03-27 | 2009-03-27 | |
| PCT/US2010/028877 WO2010111625A1 (en) | 2009-03-27 | 2010-03-26 | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009810A true MX2011009810A (es) | 2011-09-30 |
Family
ID=42332479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009810A MX2011009810A (es) | 2009-03-27 | 2010-03-26 | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120134993A1 (enExample) |
| EP (1) | EP2411407A1 (enExample) |
| JP (1) | JP2012521768A (enExample) |
| KR (1) | KR20110134494A (enExample) |
| CN (1) | CN102448984A (enExample) |
| AU (1) | AU2010229705A1 (enExample) |
| MX (1) | MX2011009810A (enExample) |
| WO (1) | WO2010111625A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| KR20150130408A (ko) * | 2013-03-15 | 2015-11-23 | 인터뮨, 인크. | 프로테오믹 ipf 마커 |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| BR112015032554A8 (pt) * | 2013-06-25 | 2018-01-23 | Sepia Pesquisa E Desenvolvimento | moduladores do receptor de bradicinina e seu uso |
| KR102060187B1 (ko) | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
| DK3041513T3 (da) | 2013-09-08 | 2020-10-26 | Kodiak Sciences Inc | Zwitterioniske faktor viii-polymerkonjugater |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
| SMT202200177T1 (it) | 2014-09-26 | 2022-05-12 | Janssen Pharmaceutica Nv | Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr |
| KR102210104B1 (ko) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| CA2969867C (en) * | 2014-12-22 | 2022-01-25 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| NZ739028A (en) | 2015-07-15 | 2023-05-26 | Genmab As | Humanized or chimeric cd3 antibodies |
| EA035586B1 (ru) * | 2015-11-30 | 2020-07-10 | Пиерис Острелиа Пти Лтд. | Новые антиангиогенные слитые белки |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| FI3592769T3 (fi) | 2017-03-09 | 2024-07-30 | Genmab As | Vasta-aineita PD-L1:tä vastaan |
| KR102706161B1 (ko) | 2017-03-31 | 2024-09-19 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법 |
| KR102758346B1 (ko) | 2017-08-04 | 2025-01-24 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US20220111043A1 (en) | 2018-09-19 | 2022-04-14 | Lava Therapeutics B.V. | Dual acting cd1d immunoglobulin |
| EP3860715A1 (en) | 2018-10-04 | 2021-08-11 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| CN120983617A (zh) | 2018-11-06 | 2025-11-21 | 健玛保 | 抗体配制剂 |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| JP2022519082A (ja) | 2019-02-01 | 2022-03-18 | ラヴァ・セラピューティクス・ベー・フェー | 新規ｃｄ４０結合抗体 |
| US20220267452A1 (en) * | 2019-07-12 | 2022-08-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-mutation type fgfr3 antibody and use therefor |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| CA3168613A1 (en) | 2020-03-18 | 2021-09-23 | Genmab A/S | Antibodies binding to b7h4 |
| EP4146175A1 (en) | 2020-05-08 | 2023-03-15 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| JP2023532807A (ja) | 2020-07-08 | 2023-07-31 | ラヴァ・セラピューティクス・エヌ・ヴイ | Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 |
| KR20230065256A (ko) | 2020-08-06 | 2023-05-11 | 비온테크 에스이 | 코로나바이러스 s 단백질용 결합제 |
| WO2022053653A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| CA3192251A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| EP4259660A1 (en) | 2020-12-10 | 2023-10-18 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors |
| CA3209454A1 (en) | 2021-02-26 | 2022-09-01 | Robertus Cornelis ROOVERS | Antibodies that bind cd123 and gamma-delta t cell receptors |
| JP2024519212A (ja) | 2021-05-07 | 2024-05-09 | ジェンマブ エー／エス | Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物 |
| US20240262924A1 (en) | 2021-06-21 | 2024-08-08 | Genmab A/S | Combination dosage regime of cd137 and pd-l1 binding agents |
| JP2024533457A (ja) | 2021-09-13 | 2024-09-12 | ヤンセン バイオテツク，インコーポレーテツド | がんの治療のためのＣＤ３３×Ｖδ２多重特異性抗体 |
| KR20240082397A (ko) | 2021-10-08 | 2024-06-10 | 젠맵 에이/에스 | Cd30 및 cd3에 결합하는 항체 |
| WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN116199744B (zh) * | 2023-03-23 | 2024-06-25 | 湖南中晟全肽生物科技股份有限公司 | 一种结合fgfr2受体的多肽及其用途 |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| AR132290A1 (es) | 2023-04-05 | 2025-06-11 | Genmab As | Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3 |
| AR133071A1 (es) | 2023-06-30 | 2025-08-20 | Genmab As | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202519261A (zh) | 2023-07-27 | 2025-05-16 | 荷蘭商拉法醫療公司 | 用於治療癌症之結合γ-δ T細胞受體之抗體 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03009408A (es) * | 2001-04-13 | 2004-01-29 | Human Genome Sciences Inc | Factor de crecimiento endotelial vascular 2. |
| US20030064053A1 (en) * | 2001-08-31 | 2003-04-03 | Shengjiang Liu | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| CA2565827A1 (en) * | 2004-05-05 | 2005-12-15 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA3128656A1 (en) * | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2009120922A2 (en) * | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
-
2010
- 2010-03-26 JP JP2012502294A patent/JP2012521768A/ja active Pending
- 2010-03-26 CN CN2010800230893A patent/CN102448984A/zh active Pending
- 2010-03-26 US US13/260,408 patent/US20120134993A1/en not_active Abandoned
- 2010-03-26 AU AU2010229705A patent/AU2010229705A1/en not_active Abandoned
- 2010-03-26 KR KR1020117025299A patent/KR20110134494A/ko not_active Ceased
- 2010-03-26 MX MX2011009810A patent/MX2011009810A/es not_active Application Discontinuation
- 2010-03-26 WO PCT/US2010/028877 patent/WO2010111625A1/en not_active Ceased
- 2010-03-26 EP EP10722828A patent/EP2411407A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN102448984A (zh) | 2012-05-09 |
| KR20110134494A (ko) | 2011-12-14 |
| WO2010111625A1 (en) | 2010-09-30 |
| AU2010229705A1 (en) | 2011-10-20 |
| US20120134993A1 (en) | 2012-05-31 |
| EP2411407A1 (en) | 2012-02-01 |
| JP2012521768A (ja) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| EP3844181B1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| CA2926262C (en) | CYSTEINE MODIFIED TYPE III FIBRONECTIN DOMAIN BINDING MOLECULES (FN3) | |
| KR20200093639A (ko) | 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조 | |
| EP4249064A2 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| NZ627103A (en) | Specific binding proteins and uses thereof | |
| GEP20115324B (en) | Tweak binding antibodies | |
| JP2015516813A5 (enExample) | ||
| PH12020500137A1 (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| JP2016525551A5 (enExample) | ||
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| WO2010042890A3 (en) | Polypeptides that bind trail-ri and trail-r2 | |
| JP2013529070A (ja) | Ｔｒａｉｌｒ２特異的多量体足場 | |
| KR20210133254A (ko) | Cd137 및 gpc3에 특이적인 신규한 융합 단백질 | |
| UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
| EP2498799A4 (en) | USE OF FGFR1 EXTRACELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATION MUTATIONS IN FGFR2 | |
| TW200801036A (en) | RAGE fusion proteins, formulations, and methods of use thereof | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| IN2012DN02981A (enExample) | ||
| NZ601591A (en) | Methods for treating pancreatic cancer | |
| TN2009000090A1 (en) | Prophylactic or therapeutic agent for canger | |
| RU2013140472A (ru) | Слитый белок антиангиогенного индуцирующего фактора и его применение | |
| WO2020247388A3 (en) | Il-2alpha receptor subunit binding compounds | |
| RU2013140184A (ru) | Fgf-r-fc слитый белок и его использование | |
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |